These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 24381243)
41. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. Stahl SM; Grady MM; Moret C; Briley M CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213 [TBL] [Abstract][Full Text] [Related]
42. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326 [TBL] [Abstract][Full Text] [Related]
43. Milnacipran and selective serotonin reuptake inhibitors in major depression. Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126 [TBL] [Abstract][Full Text] [Related]
44. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Owen RT Drugs Today (Barc); 2008 Sep; 44(9):653-60. PubMed ID: 19137120 [TBL] [Abstract][Full Text] [Related]
45. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium. Bernstein CD; Albrecht KL; Marcus DA Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481 [TBL] [Abstract][Full Text] [Related]
46. Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary. Roman MW; Wilkinson SM Issues Ment Health Nurs; 2014 Dec; 35(12):972-4. PubMed ID: 25426751 [TBL] [Abstract][Full Text] [Related]
47. A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder. Shiovitz T; Greenberg WM; Chen C; Forero G; Gommoll CP Innov Clin Neurosci; 2014 Jan; 11(1-2):10-22. PubMed ID: 24653937 [TBL] [Abstract][Full Text] [Related]
48. Milnacipran: beyond a role of antidepressant. Pae CU; Marks DM; Shah M; Han C; Ham BJ; Patkar AA; Masand PS Clin Neuropharmacol; 2009; 32(6):355-63. PubMed ID: 19620845 [TBL] [Abstract][Full Text] [Related]
49. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Puech A; Montgomery SA; Prost JF; Solles A; Briley M Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045 [TBL] [Abstract][Full Text] [Related]
50. Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats. Brunner V; Maynadier B; Chen L; Roques L; Hude I; Séguier S; Barthe L; Hermann P Drug Des Devel Ther; 2015; 9():3199-215. PubMed ID: 26150694 [TBL] [Abstract][Full Text] [Related]
51. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder. Thase ME; Gommoll C; Chen C; Kramer K; Khan A; Durgam S CNS Spectr; 2017 Dec; 22(6):475-483. PubMed ID: 28521846 [TBL] [Abstract][Full Text] [Related]
53. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. Durgam S; Chen C; Migliore R; Prakash C; Thase ME Depress Anxiety; 2019 Mar; 36(3):225-234. PubMed ID: 30675739 [TBL] [Abstract][Full Text] [Related]
54. Preclinical pharmacology of milnacipran. Briley M; Prost JF; Moret C Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():9-14. PubMed ID: 8923122 [TBL] [Abstract][Full Text] [Related]
55. Milnacipran for pain in fibromyalgia in adults. Cording M; Derry S; Phillips T; Moore RA; Wiffen PJ Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD008244. PubMed ID: 26482422 [TBL] [Abstract][Full Text] [Related]
56. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Mease PJ; Clauw DJ; Gendreau RM; Rao SG; Kranzler J; Chen W; Palmer RH J Rheumatol; 2009 Feb; 36(2):398-409. PubMed ID: 19132781 [TBL] [Abstract][Full Text] [Related]
57. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Deardorff WJ; Grossberg GT Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953 [TBL] [Abstract][Full Text] [Related]
58. Milnacipran affects mouse impulsive, aggressive, and depressive-like behaviors in a distinct dose-dependent manner. Tsutsui-Kimura I; Ohmura Y; Yoshida T; Yoshioka M J Pharmacol Sci; 2017 Jul; 134(3):181-189. PubMed ID: 28694090 [TBL] [Abstract][Full Text] [Related]
59. Vortioxetine: a New Treatment for Major Depressive Disorder. Connolly KR; Thase ME Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430 [TBL] [Abstract][Full Text] [Related]
60. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]